Madrigal Pharmaceuticals, Inc. (MDGL) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は West Conshohocken, PA, アメリカ. 現CEOは William J. Sibold.
MDGL を有する IPO日 2007-02-06, 528 名の正社員, に上場 NASDAQ Global Select, 時価総額 $12.04B.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing innovative therapeutic candidates for cardiovascular, metabolic, and liver diseases. The company's lead product, resmetirom, is a liver-directed selective thyroid hormone receptor-ß agonist currently in Phase III clinical trials for treating non-alcoholic steatohepatitis. Madrigal is also advancing MGL-3745 as a backup compound and has established a research, development, and commercialization partnership with Hoffmann-La Roche. Headquartered in West Conshohocken, Pennsylvania, the company is positioned to address significant unmet medical needs in serious metabolic and hepatic diseases.
